RGS 2064

Drug Profile

RGS 2064

Latest Information Update: 14 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Regenesance
  • Class
  • Mechanism of Action Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Brain injuries; Spinal cord injuries

Most Recent Events

  • 07 Dec 2010 RGS 2064 is available for licensing as of 07 Dec 2010. http://www.regenesance.com
  • 07 Dec 2010 Phase-I/II clinical trials in Brain injuries in Netherlands (unspecified route)
  • 07 Dec 2010 Phase-I/II clinical trials in Spinal cord injuries in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top